Cell And Gene Therapy Field Sees Opportunity Under Trump

 
• By Michael McCaughan

The cell and gene therapy field has reached an inflection point in the US as the second Trump Administration begins and advocates argue the sector could fit well with the “MAHA” agenda.

Cell and gene therapies are at a breakout point, said Alliance for Regenerative Medicine CEO Tim Hunt. (Shutterstock)
Michael McCaughan

Read more by Michael McCaughan

Michael McCaughan is a founding member of Prevision Policy LLC, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. He was previously the Editor-In-Chief of The Pink Sheet and remains a contributor to the publication.

More from Cell & Gene Therapies

More from Legislation